Lupus neuropsiquiatria


Published on

Leonor A. Barile-Fabris, MD, PhD Professor of Rheumatologo Chair, Rheumatology Department Centro Médico Nacional Siglo XXI
Mexico City, Mexico

Published in: Education, Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • 2007 recibiendo tratamiento con diclofenaco, prednisona 5mg día, cloroquina 150mg, azatioprina 100mg día. Buena respuesta y lo dejo de tomar.2009 metotrexato 10mg y prednisona 5mg. 72 hrs. posterior a medicación.
  • Infarto embolico, por ser cortical y 2 territorios diferentes., con restricción de la difusión y ADC bajo.Infección por microorganismo oportunista Toxoplasmosis por inmunosupresión o abceso cerebral por cefalea, fiebre y crisis convulsivas.Neurocirugía: Imagen isointensa en T1 e hiperintensa en T2 a nivel frontal derecho, parietal izquierdo y occipital derecho cortico subcortical con edema perilesional leve, que no refuerzan con medio de contraste.
  • Lupus neuropsiquiatria

    1. 1. The 10th International Congress on SLE Buenos Aires, Argentina Neuro-psychiatric SLE Leonor A. Barile-Fabris, MD, PhD Professor of Rheumatology Chair, Rheumatology Department Centro Médico Nacional Siglo XXI Mexico City, Mexico
    2. 2. Key points NP manifestations have been increasingly recognized. Both attribution and diagnosis remain clinical challenges. Selection of optimum treatment is complex due to scarce and heterogeneous clinical data.
    3. 3. Key issues in SLE patients with neuropsychiatric manifestations EULAR Task force on SLE- Evidence and expert-based answers • Who is at risk to develop NPSLE? • Is NPSLE common? • When to suspect NPSLE? • How can I attribute a NP event to SLE? • How do I treat NPSLE? Bertisas GK.Nat Rev Rheumatol.2010:6;1-10
    4. 4. Key points  NP symptoms are present in approximately 20 to 50% of SLE patients, frequently within the first 2 years.  These symptoms are primarily associated with a poor HRQoL and an increase in functional impairment, leading to unemployment in some cases.  Mild manifestations are common and include headache, anxiety, depression, and cognitive deficit. These, however, are not normally related to the disease. Source: Bertisas GK. Nat Rev. Rheumatol. 2010:6;1-10.
    5. 5. EULAR Recommendations for the Management of Neuropsychiatric SLE eular Neuropsychiatric SLE – General statements 1. When do they occur? -May precede, coincide, or follow the diagnosis of SLE but commonly (40-50%) occur within the first year after SLE diagnosis, -Usually (50-60%) in the presence of generalized disease activity (B). 2. Cumulative incidence of neuropsychiatric manifestations: - common (10-20%): cerebrovascular disease, seizures - relatively uncommon (3-10%): severe cognitive dysfunction, major depression, acute confusional state and peripheral nervous disorders - rare (<3%): psychosis, myelitis, chorea, cranial neuropathies, aseptic meningitis (B) Bertisas GK. Ann Rheum Dis: 69.2074-82
    6. 6. NP events at the time of diagnosis Hanly JG. Ann Rheum Dis 2101;3:529-35.
    7. 7. NP Manifestations in 88 SLE patients at the Centro Médico Nacional “La Raza”, Mexico City Manifestation Number Seizures 32 Delirium 21 Stroke 15 Pheripheral neuropathy 12 Optic neuritis 10 Transverse myelitis 4 Barile et al. Lupus 1988;7:S 107
    8. 8. GLADEL Seizures 99 30.9 Headeache 54 16.8 Psychosis 49 15.3 Delirium 47 14.6 Stroke 34 10.6 Sensitive neuropathy 33 10.3 Motor neuropathy 31 9.6 Coma 10 3.13 Aseptic meningitis 7 2.19 Transverse myelitis 7 1.7 Chorea 5 1.5 Ataxia 4 1.2 Pseudo tumor cerebri 2 0.63 Organic brain syndrome 2 0.63 Barile et al. Lupus 1998 (Suppl);7:53
    9. 9. Differing prevalences in LSE Highly heterogeneous clinical manifestations. Some are not specific or “subclinical”. Manifestations may be present despite the absence of other disease activity signs. Attribution is difficult to establish. There might be differences between inception and survival cohorts.
    10. 10. Bertisas GK.Nat Rev Rheumatol.2010:6;1-10
    11. 11. Bertisas GK.Nat Rev Rheumatol.2010:6;1-10
    12. 12. EULAR Recommendations for the Management of Neuropsychiatric SLE Neuropsychiatric SLE – General statements 4. Diagnostic work-up a) In SLE patients with new or unexplained symptoms or signs suggestive of neuropsychiatric disease, initial diagnostic work-up should be similar to that in non-SLE patients presenting with the same manifestations (D). b) Depending upon the manifestation, this may include lumbar puncture and CSF analysis (primarily to exclude CNS infection), EEG, neuropsychological assessment of cognitive function, nerve conduction studies, and neuro-imaging (MRI) to assess brain structure and function (D). c) The recommended MRI protocol (brain and spinal cord) includes conventional MRI sequences (T1/T2 FLAIR), diffusion-weighted imaging (DWI), and gadolinium-enhanced T1 sequences (B). Bertisas GK. Ann Rheum Dis: 69.2074-82 eular
    13. 13. MRI white-matter lesions in NPSLE • ↑ signal in Τ2 / FLAIR • Localized in subcortical and periventricular white matter and frontal-parietal lobe (70–80%) • Prevalence 50–60% of all patients with NPSLE …but 18–40% of non-NPSLE …no correlation with a particular NP syndrome • Cerebral atrophy, number and size of WML and cerebral infarcts correlate with severity of cognitive dysfunction In young SLE patients new MRI WMLs (especially if ≥5, ≥6-8mm, and bilateral may suggest active NPSLE
    14. 14. Case 1 2007 SLE: Arthritis, cutaneous involvement, serologic criteria. 2009 Arthritis, skin. 2010 ANA 1:280 C4 3 C3 55 Arthritis, Raynaud, digital vasculitis. Abril 2010 2011 Methilprdnisolone 3gr IV Cy single dose Anxiety, insomnia, mood disorders. CAT and MRI: Normal. CSF:Normal Steroidal psicoisis Ketiapine 200mg, Prednisone 35mg, Sertraline 50mg MMF 2 gr /d. SLEDAI 0 (low complement levels) slow prednisone tappering and MMF. Regional hospital : MMF 500mg d.
    15. 15. Case 1 (Readmission) 24/02/13: Seizures. Increased reflexes. DFH Levertiracetam, Metilprednisolone 3 gr. 03/03/13: Seizures. Increased reflexes. DFH Levertiracetam, Metilprednisolone 3 gr. Abnormal movements. Topiramate and lumbar puncture. 06/03/13: Anxiety-depression disorder.
    16. 16. IRM
    17. 17. Identifying differential diagnosis Embolic infarct. Opportunistic infection. Brain abscess. NP SLE. Brain tumor.
    18. 18. MRI Diagnosis Radiology: Infarcts (embolus), cortical, in two different territories, restricted diffusion, low ADC. Neurology: Opportunistic infection (toxoplasmosis) vs. brain abscess (headache, fever, seizures).
    19. 19. Case 1: results . TE echocardiogram: Normal Tumor IV Cy. Cardioembolic infarct NP SLE Brain gammagram Taliium 201 and Gallium 67: normal. Abscess CSF: Cels 0, RC 10, C 100%. Prot25.2 mg/dl, Gluc42 mg/dl, Cl 127 mEq/L. ANA (-), C3 y C4 0, Anti DNA 8.9, aCL 2.0 Gramm (-). Cultive (-)
    20. 20. MRI in NP SLE Multiple white matter lesions. Cerebral infarction. Cerebral hemorrhage. Venous sinus thrombosis. Atrophic changes. Spinal cord disease. Lupus 2003;12:891
    21. 21. Saggital T1 image: Clot in the Stright sinus
    22. 22. Take-home messages,case 1 There is not such thing as a typical MRI in neurolupus. Differential diagnosis comprises a wide range of causes.
    23. 23. Prognosis and treatment
    24. 24. Prognosis Poor prognosis factors: • Caucasians? • Active disease • aRO, LA, IgG aCl. Rheumatology 2004; 43:1555-1560.
    25. 25. Prognosis in 2 referral hospitals in Mexico City 29% 71% improvement no response
    26. 26. Poor prognosis, cont’d. Male gender. neuroSLICC ≥1 p = 0.0001. ↑antiDNA p= 0.21. Low complement levels p= 0.05. ↑ESR p= 0.036.
    27. 27. Poor prognosis factors Consolidation analysis: Normal ESR and complement: 85.7% improved. Low complement and high ESR : 69.2% worsened. P= 0.001
    28. 28. Treatment Barile L. Reumatol Clin. 2005;1 Supl 2: S42-5
    29. 29. eular EULAR Recommendations for the Management of Neuropsychiatric SLE Neuropsychiatric SLE – General statements 5. Therapy a) Corticosteroids and immunosuppressive therapy are indicated for neuropsychiatric manifestations felt to reflect an immune/inflammatory process (acute confusional state, aseptic meningitis, myelitis, cranial and peripheral neuropathies, and psychosis) following exclusion of non-SLE related causes (A, D). b) Anti-platelet/anti-coagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly in thrombotic cerebrovascular disease (A, D). c) The use of symptomatic therapies (e.g. anticonvulsants, antidepressants) and the treatment of aggravating factors (e.g. infection, hypertension and metabolic abnormalities) should also be considered (D). d) Anti-platelet agents may be considered for primary prevention in SLE patients with persistently positive, moderate or high, anti-phospholipid antibody titers (D).
    30. 30. • Induction Metilprednisolone (MP) 1 g/d for 3 d. • MP 1 g/d por 3 d, monthly for 4 m, then bimonthly for 6 m, and subsequently every 3 m for 1 y. or • Ciclophosphamide (Cy) 0.75 g/m2 bs monthly for 1 y, and every 3 m for another y. Ann Rheum Dis 2005;64:620–625.
    31. 31. Allocation
    32. 32. Median monthly values of visual analogue scale ratings for changes in muscular strenght in NP and TM patients P=0.04 0= No changes from basal conditions; 10= the best possible improvement
    33. 33. Seizures CFM MPD
    34. 34. Average prednisone intake/ day
    35. 35. Response to treatment MPD CY p Failure 7 1 <0.003 Improvement 11 18 <0.05 Response
    36. 36. Trevisani et al Cochrane 2008
    37. 37. Case: Female, 62 years old.  2001: Optic Neuritis in right eye.  2010: Non Hodgkin lymphoma, QxTx RxRx.  May 2010: Optic Neuritis in left eye. Hypotiroidism. ANA 1:640 H, lymphopenia, leukopenia, Neurolupus: Pdn 50mg/d and Mycophenolate.  Oct 3 2010: Hyperstetic sensitive level C5 and T7, medular discharges, hyporeflexia.
    38. 38. Oct 3 2010: Hyperstetic sensitive level C5 and T7, medular discharges, hyporeflexia. MRI: Hyper intensity with T1 enhancement, suggestive of longitudinal myelopathy From C2 to T12 with high activity in neuro-imaging
    39. 39. Selecting treatment • • • • • • IV MP Oral prednisone and high dose MMF IV Cy Plasmaphereis IV MP and IV Cy Others?
    40. 40. MP 5 g Pdn 50 mg/d      Partial improvement in sensitivity. Paraplegia. Acute confusional syndrome. Delirium. IV Cy 700mg.      Currently: 6 pulses Partial recovery Sensitivity fully recovered Motor capacity 30% recovery
    41. 41. Take-home messages: Case 2 Despite published evidence, response to treatment even within the same clinical manifestation may be heterogeneous. Transverse myelopathy has a better prognosis than longitudinal myelopathy.
    42. 42. Final considerations There are different clinical subgroups in neurolupus. Etiopathogenic mechanisms might be different, but they all seem to be related to vascular endothelium. NP SLE has a profound impact in prognosis, HRQoL and damage.